{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:09:10Z","timestamp":1777950550689,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":123,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polypharmacy leads to drug\u2013drug interactions (DDIs) with direct\u2010acting antivirals (DAAs). We quantified the DDI burden (Liverpool categories) and evaluated its association with effectiveness and safety. We assessed renal function as a predictor of adverse events (AEs) and reported loss to follow\u2010up (LTFU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 145 adults with chronic hepatitis C treated with glecaprevir\/pibrentasvir (GLE\/PIB) or sofosbuvir\/velpatasvir (SOF\/VEL) between February 2018 and October 2024. The primary endpoint was sustained virological response 12 weeks after the end of treatment (SVR12); when SVR12 was missing, SVR24 was substituted (hierarchical SVR). Concomitant drugs were screened using the Liverpool HEP Drug Interaction Checker. The predictors of AEs were assessed using multivariable logistic regression and receiver operating characteristic analysis. A conservative intention\u2010to\u2010treat analysis included missing SVR data as a failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median patient age was 67 years, and 23.4% of patients had cirrhosis. Polypharmacy (\u2265\u20095 drugs) occurred in 26.9% of patients, DDIs in 50.3%, multiple DDIs in 14.5%, and contraindicated pairs in 1.4% (all GLE\/PIB). AEs occurred in 16.6% of patients, were largely Grades 1\u20132, and began around Week 2. LTFU was 11.0%. The hierarchical SVR was 99.2%, whereas the conservative analysis was 88.3%. A Cr\u2009concentration \u2265 0.86\u2009mg\/dL independently predicted AEs (adjusted OR 3.4; 95% CI 1.24\u20139.2), whereas DDI burden and polypharmacy did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite frequent DDIs, DDI burden was not independently associated with SVR or AEs. DAA therapy was highly effective and well tolerated. Renal function showed a modest association with AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/ijh\/5499912","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:41:15Z","timestamp":1777880475000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Drug\u2013Drug Interaction Burden of Direct\u2010Acting Antiviral Therapy for Hepatitis C: A Single\u2010Center Community Hospital Analysis"],"prefix":"10.1155","volume":"2026","author":[{"given":"Satoru","family":"Okabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-026X","authenticated-orcid":false,"given":"Kengo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-9003","authenticated-orcid":false,"given":"Tsutomu","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"e_1_2_11_1_2","doi-asserted-by":"publisher","DOI":"10.2957\/kanzo.65.368"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-025-00442-5"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000858"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40506-020-00231-8"},{"key":"e_1_2_11_5_2","volume-title":"Medication Safety in Polypharmacy: Technical Report","author":"World Health Organization","year":"2019"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S394467"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10402-y"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_2_11_9_2","volume-title":"HEP Drug Interaction Checker","author":"University of Liverpool","year":"2025"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.039"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27366"},{"key":"e_1_2_11_12_2","first-page":"1034","article-title":"Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease 2012","volume":"54","author":"Japanese Society of Nephrology","year":"2012","journal-title":"Nihon Jinzo Gakkai Shi."},{"key":"e_1_2_11_13_2","volume-title":"Glecaprevir\/Pibrentasvir \u2014 Carbamazepine (Liverpool HEP Interactions)","author":"University of Liverpool","year":"2025"},{"key":"e_1_2_11_14_2","volume-title":"MAVYRET (Glecaprevir\/Pibrentasvir) Full Prescribing Information","author":"AbbVie I.","year":"2025"},{"key":"e_1_2_11_15_2","volume-title":"EPCLUSA (Sofosbuvir\/Velpatasvir) Full Prescribing Information","author":"Gilead S. I.","year":"2022"},{"key":"e_1_2_11_16_2","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"National Cancer Institute","year":"2021"},{"key":"e_1_2_11_17_2","volume-title":"Overview of the Healthcare Insurance","author":"Ministry of Health LaWJ","year":"2025"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.18176\/resp.00095"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1391-5"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1503-x"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235529"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12855"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232773"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6591-20"}],"container-title":["International Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ijh\/5499912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/ijh\/5499912","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ijh\/5499912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:41:17Z","timestamp":1777880477000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/ijh\/5499912"}},"subtitle":[],"editor":[{"given":"Sreeja","family":"Dattachoudhury","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/ijh\/5499912"],"URL":"https:\/\/doi.org\/10.1155\/ijh\/5499912","archive":["Portico"],"relation":{},"ISSN":["2090-3448","2090-3456"],"issn-type":[{"value":"2090-3448","type":"print"},{"value":"2090-3456","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5499912"}}